ARCA BIOPHARMA

ABIO NASDAQ
7.14
+0.24
+3.48%
After Hours: 7.14 0 0.00% 16:07 07/22 EDT
Open
6.85
Prev Close
6.90
High
7.14
Low
6.79
Volume
55.86K
Avg Vol (3M)
790.93K
52 Week High
23.04
52 Week Low
4.725
% Turnover
3.84%
Market Cap
10.39M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers ARCA BIOPHARMA ABIO stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
MORE >

Recently

Name
Price
%Change